News tagged with emtricitabine
Results of a major HIV prevention trial suggest that daily use of a product – whether a vaginal gel or an oral tablet – does not appear to be the right approach for preventing HIV in young, unmarried African women.
HIV & AIDS Mar 04, 2013 | not rated yet | 0
A novel head-to-head study looking at differences in how the antiretroviral (ARV) drug tenofovir gets absorbed in the body as either an oral tablet or a vaginal gel found tenofovir gel can achieve substantially higher concentrations ...
HIV & AIDS Jan 30, 2013 | not rated yet | 0
Replacing the combination of brand-name, antiretroviral drugs currently recommended for control of HIV infection with soon-to-be-available generic medications could save the U.S. health care system almost $1 billion a year ...
HIV & AIDS Jan 14, 2013 | not rated yet | 0
Several large clinical trials have demonstrated that a daily oral dose of one or two antiretroviral drugs used to treat HIV infection can prevent infection in an approach known as pre-exposure prophylaxis, or PrEP. The level ...
HIV & AIDS Sep 13, 2012 | not rated yet | 0
The UN agency tasked with fighting AIDS on Tuesday welcomed the decision by the United States to allow the use of an HIV prevention pill for the first time.
HIV & AIDS Jul 17, 2012 | not rated yet | 0
(AP) The Food and Drug Administration on Monday approved the first drug shown to reduce the risk of HIV infection, the latest milestone in the 30-year battle against the virus that causes AIDS.
HIV & AIDS Jul 16, 2012 | 4 / 5 (1) | 0
Various trials examining the use of anti-retroviral drugs in healthy heterosexuals as a way to prevent HIV have shown drastically different results, research showed Wednesday.
HIV & AIDS Jul 11, 2012 | not rated yet | 0
People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers ...
HIV & AIDS Jul 10, 2012 | not rated yet | 0
New once-daily 'Quad' pill for HIV is safe, effective alternative to traditional antiretroviral regimens
A new once-daily pill combining three antiretrovirals and a booster molecule is a safe and effective alternative to two widely used drug regimens for newly diagnosed HIV-positive adults who have had no previous treatment. ...
HIV & AIDS Jun 28, 2012 | not rated yet | 0
While immediate postexposure treatment for suspected HIV is critical, pre-exposure preventive treatment is a newer method that may be effective for people in high-risk groups, states a review of evidence published in CMAJ (Canad ...
HIV & AIDS May 28, 2012 | not rated yet | 0
US health advisers on Thursday urged regulators to approve Truvada, made by Gilead Sciences, as the first preventive pill against HIV/AIDS instead of just a treatment for infected people.
HIV & AIDS May 10, 2012 | not rated yet | 0
A once-a-day pill to help prevent HIV infection could significantly reduce the spread of AIDS, but only makes economic sense if used in select, high-risk groups, Stanford University researchers conclude in a new study.
HIV & AIDS Apr 16, 2012 | not rated yet | 0 |
New research from the University of North Carolina at Chapel Hill schools of medicine and pharmacy may help explain the failure of some recent clinical trials of prevention of HIV infection, compared to the ...
HIV & AIDS Dec 07, 2011 | not rated yet | 0 |
A large-scale clinical trial evaluating whether daily use of an antiretroviral-containing oral tablet or vaginal gel can prevent HIV infection in women is being modified because an interim review found that the gel, an investigational ...
HIV & AIDS Nov 28, 2011 | not rated yet | 0
A large-scale clinical trial evaluating whether daily use of an oral tablet or vaginal gel containing antiretroviral drugs can prevent HIV infection in women is being modified because an interim review found that the study ...
HIV & AIDS Sep 28, 2011 | not rated yet | 0
Emtricitabine (FTC), with trade name Emtriva (formerly Coviracil), is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection in adults and children.
Emtricitabine is also marketed in a fixed-dose combination with tenofovir (Viread) under the brand name Truvada. A fixed-dose triple combination of emtricitabine, tenofovir and efavirenz (Sustiva, marketed by Bristol-Myers Squibb) was approved by the U.S. Food and Drug Administration (FDA) on July 12, 2006 under the brand name Atripla.
For more information about Emtricitabine, read the full article at
This text uses material from Wikipedia and is available under the GNU Free Documentation License.